Technology Transfer Office
Actualité - Partnership

Startup Magic LEMP wins the AI4Curie challenge

Institut Curie
Longstanding partners Institut Curie and Swiss Life are pleased to announce the result of the AI4Curie challenge. Launched last January, it consisted in identifying a project aimed at better predicting, through AI, the response to immunotherapy treatment for patients with lung cancer. On september 16th, the jury selected the startup Magic LEMP for its project "CaPrICoRN". The start-up will be supported by the best experts of Institut Curie and by a financial support of 60k euros granted by Swiss Life.
AI4 Curie

Institut Curie and Swiss Life are pleased to announce the result of the challenge, launched last January, to identify a project aimed at better predicting, through AI, the response to immunotherapy treatment for patients with lung cancer. The jury - following the auditions held on September 16th - selected the startup Magic LEMP for its project "CaPrICoRN". The implementation of the selected project should start at the end of the year on the premises of Institut Curie with a financial support of 60,000 euros granted by Swiss Life. The winners will be supported by the best experts to set up their proof of concept (or POC).

The winning startup and its "CaPrICoRN" project

Magic LEMP, startup selected for its "CaPrICoRN" project (Calibration of Neuron Network Constructed Immunotherapy Protocols) develops new machine learning and AI approaches to solve complex problems in many areas. It focuses on the explainability of its algorithms, a concept that is at the heart of the project presented to the AI4Curie jury. It is this explainability that made the difference among all the candidates, as explained by Dr Alain Livartowski, oncologist and advisor to the Data Director of Institut Curie:

Today, what is not explained is why, for the same tumor and the same treatment, some patients respond and heal, while others do not and develop toxicities. Explainability will allow us to understand this in order to progress in the understanding of the disease and the response to treatment.

The project proposed by the startup will enable doctors to make a personalized decision based on patient data, as is pleased to note the president of the jury, Pr Nicolas Girard, lung oncologist at Institut Curie and head of Institut du Thorax Curie-Montsouris:

As a medical oncologist, we are required to make complex decisions every day by integrating all patient data. The project proposed allows us to formalize these elements with one objective: improve the care of our patients.

It is important to emphasize the importance of this data: the data generated during routine care for a patient are "real life data". Once extracted from computerized patient records and analyzed by Artificial Intelligence (AI) methods, it helps in the choice of medical decisions. Today, health data can save lives. In oncology, treatments are evolving rapidly and analyzing this "real-life data" is critical.

AI4Curie, a challenge carried by two longstanding partners

"I was particularly impressed by the high level projects presented at the audition, but only one had to be chosen; I am now looking forward to following the project in question. It was quite legitimate for us to be associated with such a challenge, on the one hand because we have been a great supporter of Institut Curie over the years through various projects and, on the other hand, because we feel we have a societal role to play as a health insurer", said Pierre François, CEO of SwissLife Prévoyance et Santé and member of the AI4Curie jury.

On January 22nd, Institut Curie and Swiss Life officially launched this challenge for startups and researchers specializing in AI who had to answer a clinical question: "Is it possible to predict the response to immunotherapy treatment based on the analysis of images of patients with lung cancer?” - a promising treatment that is still not effective for all patients.

Candidates had until the end of April to submit their applications, but this deadline was extended to June 30th due to the COVID-19 health crisis. The jury composed of experts in oncology and artificial intelligence, among others, and chaired by Pr Nicolas Girard, selected three startups to audition.

Institut Curie is a world leader in the fight against cancer. The MC21 project for Marie Curie in the 21st century, aims to do everything possible to ensure that tomorrow's post-cancer world will be a reality for every patient. One of the first milestones of the MC21 project was the creation of the Center for Cancer Immunotherapy, which brings together researchers, doctors, caregivers and patients in a single location. In addition, Institut Curie joined forces with Institut Mutualiste Montsouris (IMM) to create the Institut du Thorax Curie-Montsouris, in order to offer patients comprehensive and coordinated care. Finally, to accompany the revolution in health data, Institut Curie has created a cross-functional structure, the Data Department, which supports its researchers and physicians in structuring, making available and promoting health and research data. Today, Institut Curie is at the forefront of the use of data and artificial intelligence to improve research and patient treatment.

AI at the service of immunotherapy: a revolution announced for cancer research and patient treatment

AI is a revolution for cancerology because it will allow us to better classify tumors, better predict treatment response and improve prognosis.

said Dr. Alain Livartowski.

In this age of artificial intelligence, it is essential to work with these masses of data, i.e. to identify and interpret them. This is the case at Institut Curie, which has 500,000 patient files and is a pioneer in the computerization of clinical data. Medical records have been computerized there for over 20 years and there is a shared medical record that structures medical information in a precise way to provide usable quality data.










Every year, more than 31,000 men and more than 15,000 women are affected by lung cancer. Second cause of cancer for men, after the prostate, and third cause of cancer for women, after the breast and colon-rectum, it occurs on average at the age of 66 and remains the leading cause of cancer mortality in France with more than 33,000 deaths each year, notably due to tobacco.